External and internal validity of open label or double-blind trials in oral anticoagulation: better, worse or just different?

Rivaroxaban versus Warfarin in Nonvalvular Atrial Fibrillation

(2011) Manesh R. Patel et al.   NEW ENGLAND JOURNAL OF MEDICINE

Participant expectancies in double-blind randomized placebo-controlled trials: potential limitations to trial validity

(2010) Ben Colagiuri   Clinical Trials

Oral Rivaroxaban for Symptomatic Venous Thromboembolism

(2010)   NEW ENGLAND JOURNAL OF MEDICINE

Double-blindness protects scientific validity

(2009) C. D. FURBERG et al.   JOURNAL OF THROMBOSIS AND HAEMOSTASIS

Open-label trials and drug registration: a European regulator’s view

(2009) M. CASTEELS et al.   JOURNAL OF THROMBOSIS AND HAEMOSTASIS

Dabigatran versus Warfarin in Patients with Atrial Fibrillation

(2009) Stuart J. Connolly et al.   NEW ENGLAND JOURNAL OF MEDICINE

Dabigatran versus Warfarin in the Treatment of Acute Venous Thromboembolism

(2009) Sam Schulman et al.   NEW ENGLAND JOURNAL OF MEDICINE

Double-blind studies are not always optimum for evaluation of a novel therapy: the case of new anticoagulants

(2008) H. R. BÜLLER et al.   JOURNAL OF THROMBOSIS AND HAEMOSTASIS